Shire Announces the Organize Your Stuff Contest Winners
North Carolina technical assistant wins a free space makeover
PHILADELPHIA, Oct. 14, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the winners of the Organize Your Stuff contest, which was designed to help adults organize their space and reduce clutter. Sydney Bloom, 28, from Charlotte, NC was chosen as the grand prize winner after submitting a picture of her craft room and the reason she needed help organizing it.
To help Sydney achieve her organizational goals, Monica Friel, president and founder of Chaos to Order, a respected professional organizing service, designed and implemented an individualized organization plan. The makeover kicked off in August 2014. Pictures of the grand prize winner's space makeover and additional information about the contest, including a complete list of contest winners, can be found by visiting: OrganizeYourStuffContest.com. This site also includes a link to Shire's UDotheRest website offering apps, tips and tools designed to help make everyday tasks more manageable.
"It was a pleasure to assist Sydney in conquering clutter and maximizing her space," said Monica Friel. "Getting organized can be challenging for some people, but it may be managed with some assistance. Using my expertise as a professional organizer, my goal was to create an organized system that Sydney may find beneficial."
From April 7, 2014 to June 30, 2014, 440 adults ages 18 and over submitted a photo of a space they needed help organizing to OrganizeYourStuffContest.com. The submissions included a description of the space, why they were motivated to organize it, and the issues that kept them from organizing the space on their own. Leading up to the announcement of the grand prize winner, Christa Barnell, Grand Haven, MI, Kim Bradley, Cary, NC and Morgan Whitaker, Millville, NJ each received a tablet and gift card to purchase apps after winning the three random drawings held during the contest.
"The success of the contest demonstrates a real need for the resources Shire provides through UDotheRest.com," said Perry Sternberg, Head of the Neuroscience Business Unit at Shire. "As leaders in the ADHD space, Shire understands the challenges individuals with ADHD may face."
The UDotheRest website was developed by Shire, the maker of Vyvanse® (lisdexamfetamine dimesylate). Vyvanse is a prescription medication for the treatment of ADHD in patients 6 and above. It may improve symptoms of impulsivity, hyperactivity and inattention in patients with ADHD. The rest is up to them. While UDotheRest.com may be helpful for adults with ADHD, the apps, tips, and tools collected there are available for any adult who is looking for a little assistance in these areas.
Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep in a safe place to prevent misuse and abuse. Selling or sharing Vyvanse may harm others and is illegal.
Information about Vyvanse
Vyvanse (lisdexamfetamine dimesylate) is indicated for the treatment Attention- Deficit/Hyperactivity Disorder (ADHD) in patients 6 years and above. Vyvanse capsules are currently available in six once-daily dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
ADDITIONAL IMPORTANT SAFETY INFORMATION
Do not take Vyvanse if you or your child:
- is taking or has taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI
- is sensitive to, allergic to, or had a reaction to other stimulant medicines
- Some people have had the following problems when taking stimulant medicines, such as Vyvanse:
1. Heart-related problems including:
- sudden death in people who have heart problems or heart defects
- sudden death, stroke and heart attack in adults
- increased blood pressure and heart rate
Tell your doctor if you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. The doctor should check your or your child's blood pressure and heart rate regularly during treatment.Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Vyvanse.
2. Mental (psychiatric) problems including:
- new or worse behavior and thought problems
- new or worse bipolar illness
In Children and Teenagers
new psychotic symptoms such as:
- seeing things or hearing voices that are not real
- believing things that are not true
- being suspicious
- new manic symptoms
- new psychotic symptoms such as:
Tell your doctor about any drug abuse, alcohol abuse or mental problems that you or your child has had, or about a family history of suicide, bipolar illness, or depression.
Call your doctor right away if you or your child has any new or worsening mental symptoms or problems while taking Vyvanse.
3. Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud's phenomenon]:
- Fingers or toes may feel numb, cool, painful, sensitive to temperature and/or change color from pale, to blue, to red
Call your doctor right away if you have or your child has any of these signs or symptoms or develops unexplained wounds on fingers or toes while taking Vyvanse.
- Tell the doctor if you or your child is pregnant, breast-feeding, or plans to become pregnant or breast-feed.
Vyvanse may cause serious side effects, including:
- slowing of growth (height and weight) in children. Your child should have his or her height and weight checked often while taking Vyvanse (lisdexamfetamine dimesylate). The doctor may stop treatment if a problem is found during these check-ups.
The most common side effects reported in studies of Vyvanse were:
- decreased appetite
- dry mouth
- loss of appetite
- trouble sleeping
- upper stomach pain
- weight loss
For additional safety information, click here for Prescribing Information and Medication Guide and discuss with your doctor.
Attention-Deficit/Hyperactivity Disorder is a neurobehavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development and is inconsistent with developmental level.
ADHD is one of the most common childhood psychiatric disorders. An estimated 11 percent (6.4 million) of US school-aged children have been diagnosed with ADHD in their lifetime, based on the 2011/12 National Survey of Children's Health, in which parents were asked if a health care practitioner had ever told them their child had ADD or ADHD. Although many people tend to think of ADHD as a childhood problem, 60% to 85% of children with ADHD may continue to meet the criteria for the disorder during their teenage years. Nearly 50% of children with ADHD may continue to meet the criteria for the disorder in adulthood, based on parent report. The disorder is estimated to affect 4.4 percent of US adults aged 18 to 44 based on results from the National Comorbidity Survey Replication. When this percentage is extrapolated to the full US population aged 18 and over, approximately 10.5 million adults are estimated to have ADHD. Drug treatment may not be appropriate for all patients with ADHD.
The specific etiology of ADHD is unknown. The diagnosis is made utilizing criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5®) or International Classification of Diseases, 10th revision (ICD-10). Only a trained health care professional can evaluate and diagnose ADHD.
Although there is no cure for ADHD, there are accepted treatments that have been demonstrated to improve symptoms. Standard treatments include educational approaches, psychological therapies which may include behavioral modification, and/or medication.
NOTES TO EDITORS
Shire aspires to be as brave as the people we help.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal Disorders, and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
Vyvanse® is a registered trademark of Shire LLC.